Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Miles Carroll

Professor of Emerging Viruses

Carroll Group: High Consequence Emerging Viruses Group

HOST-PATHOGEN INTERACTIONS OF HIGH CONSEQUENCE EMERGING VIRUSES

Our work centres around high consequence emerging viral infections. Currently, our focus is on Ebola, Lassa fever and SARS-CoV-2. We are interested in host-pathogen interactions, development of anti-virals and recently we have been looking at the IgG response following SARS-CoV-2 infection and/or vaccination in humans and animal models. To further support this work we are using a live virus neutralisation, multiplex immunoassays and novel ACE2 inhibition assay to inform on the ability of serum to neutralise SARS-CoV-2 variants of concern (VOC). We are also interested in the innate response to viral infection, particularly activation and/or evasion of the complement system

Recent publications

The development of biologically contained Sudan virus as an alternative and safe tool for fundamental filovirus research.

Journal article

Verlinden J. et al, (2026), Emerging microbes & infections, 15

Cephalosporins are potent SARS-CoV-2 main protease inhibitors

Journal article

Muntean D-G. et al, (2026), European Journal of Medicinal Chemistry, 316, 118995 - 118995

Identifying molecular signatures underpinning treatment responses to novel therapeutics influencing COVID-19 outcomes.

Journal article

Ackland J. et al, (2026), Journal of immunology (Baltimore, Md. : 1950), 215

ACE2 inhibition ELISA is an effective surrogate for SARS-CoV-2 live virus neutralisation

Journal article

Tipton T. et al, (2026), Vaccine, 72, 128123 - 128123

More publications